Johnson & Johnson Total Long-Term Assets 2010-2024 | JNJ
Johnson & Johnson total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
- Johnson & Johnson total long-term assets for the quarter ending June 30, 2024 were $123.271B, a 5.99% decline year-over-year.
- Johnson & Johnson total long-term assets for 2023 were $114.063B, a 13.64% decline from 2022.
- Johnson & Johnson total long-term assets for 2022 were $132.084B, a 9.13% increase from 2021.
- Johnson & Johnson total long-term assets for 2021 were $121.039B, a 2.12% decline from 2020.
Johnson & Johnson Annual Total Long-Term Assets
(Millions of US $) |
| 2023 |
$114,063 |
| 2022 |
$132,084 |
| 2021 |
$121,039 |
| 2020 |
$123,657 |
| 2019 |
$112,454 |
| 2018 |
$106,921 |
| 2017 |
$114,215 |
| 2016 |
$76,176 |
| 2015 |
$73,201 |
| 2014 |
$74,614 |
| 2013 |
$76,276 |
| 2012 |
$75,231 |
| 2011 |
$59,328 |
| 2010 |
$55,601 |
| 2009 |
$55,141 |
Johnson & Johnson Quarterly Total Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
$123,271 |
| 2024-03-31 |
$114,964 |
| 2023-12-31 |
$114,063 |
| 2023-09-30 |
$112,358 |
| 2023-06-30 |
$131,119 |
| 2023-03-31 |
$131,581 |
| 2022-12-31 |
$132,084 |
| 2022-09-30 |
$109,888 |
| 2022-06-30 |
$113,877 |
| 2022-03-31 |
$117,931 |
| 2021-12-31 |
$121,039 |
| 2021-09-30 |
$119,339 |
| 2021-06-30 |
$122,671 |
| 2021-03-31 |
$120,024 |
| 2020-12-31 |
$123,657 |
| 2020-09-30 |
$113,115 |
| 2020-06-30 |
$112,488 |
| 2020-03-31 |
$110,791 |
| 2019-12-31 |
$112,454 |
| 2019-09-30 |
$111,188 |
| 2019-06-30 |
$113,318 |
| 2019-03-31 |
$108,040 |
| 2018-12-31 |
$106,921 |
| 2018-09-30 |
$108,509 |
| 2018-06-30 |
$109,927 |
| 2018-03-31 |
$113,857 |
| 2017-12-31 |
$114,215 |
| 2017-09-30 |
$113,829 |
| 2017-06-30 |
$114,018 |
| 2017-03-31 |
$81,571 |
| 2016-12-31 |
$76,176 |
| 2016-09-30 |
$77,050 |
| 2016-06-30 |
$73,523 |
| 2016-03-31 |
$73,493 |
| 2015-12-31 |
$73,201 |
| 2015-09-30 |
$69,772 |
| 2015-06-30 |
$71,035 |
| 2015-03-31 |
$70,398 |
| 2014-12-31 |
$74,614 |
| 2014-09-30 |
$72,124 |
| 2014-06-30 |
$75,081 |
| 2014-03-31 |
$75,961 |
| 2013-12-31 |
$76,276 |
| 2013-09-30 |
$74,757 |
| 2013-06-30 |
$73,052 |
| 2013-03-31 |
$74,308 |
| 2012-12-31 |
$75,231 |
| 2012-09-30 |
$74,160 |
| 2012-06-30 |
$74,135 |
| 2012-03-31 |
$59,187 |
| 2011-12-31 |
$59,328 |
| 2011-09-30 |
$58,378 |
| 2011-06-30 |
$59,441 |
| 2011-03-31 |
$58,929 |
| 2010-12-31 |
$55,601 |
| 2010-09-30 |
$55,530 |
| 2010-06-30 |
$53,277 |
| 2010-03-31 |
$54,580 |
| 2009-12-31 |
$55,141 |
| 2009-09-30 |
$55,956 |
| 2009-06-30 |
$51,944 |
| 2009-03-31 |
$51,261 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$399.964B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
